New: NCI-funded clinical trial search
Mednet Logo
CommunityRadiation Oncology

Radiation Oncology

Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.

Recent Discussions

How do you risk stratify patients with MRI guided prostate biopsies?

1
4 Answers

Mednet MemberInvited Expert
Radiation Oncology · Rutgers Cancer Institute of New Jersey

If the patient has had standard template biopsies and targeted biopsies, I only consider that standard biopsies in the quantification of the proportion of cores involved since the data used to derive the prognostic significance of this feature was based on standard template biopsies not targeted cor...

Would you offer radiation therapy post lumpectomy for a small melanoma oligometastasis with negative margins?

2 Answers

Mednet MemberInvited Expert
Radiation Oncology · Varian Medical Systems/Allegheny health network

I don’t know if RT will have benefits for melanoma with negative margins.

How, if at all, does your approach to adjuvant chemoradiation differ with proton beam radiation vs. conventional photon radiation for H&N Cancers?

3 Answers

Mednet Member
Radiation Oncology · Michigan Healthcare Professionals, PC

As there is no prospective data for protons over photons in head and neck cancer, despite the proliferation in utilization, I would not feel comfortable treating this way unless it was the only option.In addition, recent reports indicate a relatively high risk of mandibular ORN, which is hardly seen...

About Mednet

A community where doctors find answers to medicine's toughest questions.

  • Verified, credentialed physicians
  • 45,000+ members across 24 specialties
  • Free CME and MOC credit

Does acute radiation cystitis cause microscopic hematuria and pyuria?

1
1 Answers

Mednet MemberInvited Expert
Radiation Oncology · Rutgers Cancer Institute of New Jersey

Radiation cystitis is the diagnosis.

How do you approach a urethral carcinoma s/p non-oncologic resection?

1 Answers

Mednet MemberInvited Expert
Radiation Oncology · Varian Medical Systems/Allegheny health network

I have treated a few of them. It usually tends to be clear cell histology. For a non oncologic resection, I treat with chemo RT and have had mixed results.

What criteria do you use to determine the resectability of mucosal melanoma of the H&N region?

1 Answers

Mednet MemberInvited Expert
Radiation Oncology · UCLA Medical Center

Obviously, the best specialist to answer the posted question would be a H&N surgeon. As a Rad Onc enthusiast who conducted a retrospective study about the subject long ago (Lee et al., PMID 8302112), I’ll provide my own 2-cents here:Mucosal melanoma (MucMlnm) of the H&N is a relatively uncommon mali...

Do you have any precautions to your injury to the uterine artery when placing interstitial needles as ‘ovoid extenders’ to cover parametrial disease in cervical T&O procedures?

1 Answers

Mednet MemberInvited Expert
Radiation Oncology · Varian Medical Systems/Allegheny health network

When using oblique needles, it does come close to parametrial vessel, and the risk of bleeding is increased. Some use Doppler ultrasound to identify and avoid needles in vessels. What we do is tend to usually not push the oblique needle beyond 2 cm and adjust later on CT if needed and take precautio...

If using hyperthermia in breast reirradiation, what type of protocol do you follow?

1
1 Answers

Mednet MemberInvited Expert
Radiation Oncology · Allegheny Health Network, Pittsburgh

There are a few options we consider when using hyperthermia Hyperthermia and RT are given twice weekly, ex. 32-40 Gy/8-10 fx with hyperthermia Daily RT with twice weekly hyperthermia- 40/15, or 50/25 for example, with twice weekly hyperthermia. Sometimes consider concurrent capecitabine as well.

What is the role of local control +/- whole lung irradiation in a patient with relapsed/refractory Ewing sarcoma to the hilum plus multiple lung nodules?

1
2 Answers

Mednet MemberInvited Expert
Radiation Oncology · The Ohio State University - James Cancer Hospital and Solove Research Institute

I would boost residual thoracic disease to at least the usual Ewings gross disease dose of 55.8 (total, including WLI dose). Doses in this range are well known to be safe in the thorax and this multiply relapsed disease is likely to be more treatment refractory than primary disease. SBRT boost seems...

Is there any reason to hold fulvestrant during SBRT to an oligoprogressive nodule?

1 Answers

Mednet MemberInvited Expert
Radiation Oncology · Abramson Cancer Center, University of Pennsylvania

No.